CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved
Donald S. Robbins, President and CEO of CSMG Technologies, said, "This keyU.S. patent approval re-enforces our patent portfolio and expands LTC'scommercial possibilities while increasing our shareholder value. Our strongpatent portfolio, and a disruptive technology as well as ISO 13485:2003certification for the design and manufacture of Bipolar Forceps Systems,recent US FDA 510(k) clearance and European Union C. E. Mark certification onLTC's VAD.400 electrosurgery generator and two instruments puts us in anexcellent position of competing in global medical device markets."
"Our LTC team has presented comparative results at conferences with theLTC bipolar sealing system and shown that LTC's bipolar sealing system hasbroad applications. Additionally, in preparation for launching LTC'scommercial product I early 2009, LTC has begun building inventory for bothLTC's electro surgery generator and hand instrument for duct and vesselsealing, and are in discussions with interested international medical devicecompanies and distributors," Mr. Robbins added.
About Live Tissue Connect
LTC's surgical tissue bonding / welding device is a patented platformtechnology that bonds and reconnects human soft tissue through fusion, incontrast with conventional wound closing devices such as sutures, staples,sealant, or glues. LTC currently holds a total of approximately 31 patents andpending patents in the U.S., Australia, Canada, European Union, Ukraine andother countries.
For further information on Live Tissue Connect, please visit the LTCwebsite at http://www.livetissueconnect.com.
For further information on CSMG Technologies and its various subsidiaries,please visit our website at http://www.csmgtechinternational.com.
Sign up to receive CSMG Technologies automated email press releases andother notifications: Please go to:http://www.csmgtechinternational.com/contact_information.html and fill-ininformation.
This press release may contain forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934 as amended (theExchange Act), including all statements that are not statements of historicalfact regarding the intent, belief or current expectations of the company, itsdirectors or its officers with respect to, among other things: (i) thecompany's financing plans; (ii) trends affecting the company's financialcondition or results of operations; (iii) the company's growth strategy andoperating strategy; and (iv) the declaration and payment of dividends. Thewords "may," "would," "will," "expect," "estimate," "anticipate," "believe,""intend" and similar expressions and variations thereof are intended toidentify forward-looking statements. Investors are cautioned that any suchforward-looking statements are not guarantees of future performance andinvolve risks and uncertainties, many of which are beyond the company'sability to control, and that actual results may differ materially from thoseprojected in the forward-looking statements as a result of various factors.
SOURCE CSMG Technologies, Inc.
You May Also Like